Baxter reports Q4 sales $3.9B, full-year GAAP loss of $4.83 per share; spinoff update

BAXTER INTERNATIONAL INC

2022-FY EPS reported -$4.83 revenue$15,113,000,000

Q4 revenue $3.9B (+11% reported, +17% constant currency); GAAP EPS $0.36, adjusted EPS $0.88.
Full-year sales $15.1B (+18% reported); GAAP diluted EPS loss ($4.83); adjusted EPS $3.50.
Company reiterates plans to spin off Renal Care and Acute Therapies into a new kidney care company.
CEO cites ongoing macroeconomic and supply chain headwinds weighing on performance.
Guidance for 2023 provided in full press release; no specific numbers in excerpt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

BAXTER INTERNATIONAL INC reported financial results for the fourth quarter and full year ended Dec. 31, 2022.

Period: the fourth quarter and full year ended Dec. 31, 2022
Result: reported results

Exact text from the filing

On February 9, 2023 , Baxter International Inc. (the Company) issued an earnings press release for the period ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

BAXTER INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001628280-23-002862

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.